» Articles » PMID: 34183792

Teprotumumab for Thyroid Eye Disease: Early Response is Not Required for Benefit

Overview
Journal Eye (Lond)
Specialty Ophthalmology
Date 2021 Jun 29
PMID 34183792
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: In recent trials, 50% of patients treated with teprotumumab for thyroid eye disease had significant improvements in proptosis at 6 weeks. However, a small subgroup of patients did not have a significant response by week 12. We examine the outcomes at week 24 in patients from both trials who had little or no proptosis response at week 12.

Design: In this post hoc analysis, data from teprotumumab-treated patients in the placebo-controlled randomized phases 2 and 3 trials were reviewed.

Methods: Patients treated with teprotumumab or placebo with a ≤2 mm reduction from baseline in proptosis at week 12 and completed assessments at both the weeks 12 and 24 visits were included. The main outcome measures were a change in proptosis, clinical activity score (CAS) and diplopia in response to teprotumumab therapy at baseline and weeks 6, 12, 18, and 24.

Results: From the phases 2 and 3 studies, 24 patients from the treated and placebo groups were included for analysis (48 total). In the teprotumumab group, of the 24 who had no improvement in proptosis (≥2 mm from baseline) at 12 weeks, 15 (63%) demonstrated a clinically significant improvement at week 24. No patients from the 24 placebo patients had a clinically significant improvement in proptosis at 12 weeks, and 24 weeks. At week 12, 22 patients (92%) in the teprotumumab group had a significant reduction in the CAS (≥2 points) and at 24 weeks all patients achieved this reduction. At week 12, 11 (46%) patients from the placebo group had a significant improvement, while 10 (42%) had a significant improvement at 24 weeks. 22 of the 24 patients (92%) in the teprotumumab group had a diplopia grade > 0 at baseline. At week 12, 12 of the 22 (55%) had improvement in diplopia ≥ 1 grade. By week 24, 16 patients (73%) had an improvement in diplopia ≥ 1 grade. In the placebo group, 15 (63%) had significant diplopia. At week 12, 3 (20%) from this group had improvement in diplopia ≥ 1 grade, while at 24 weeks this number rose to 4 (27%).

Conclusions: There is variability in the time taken to manifest a clinically significant response to teprotumumab, some patients my need a longer time to respond.

Citing Articles

Application of artificial intelligence in the assessment of thyroid eye disease (TED) - a scoping review.

Chng C, Zheng K, Kwee A, Lee M, Ting D, Wong C Front Endocrinol (Lausanne). 2024; 14:1300196.

PMID: 38174334 PMC: 10761414. DOI: 10.3389/fendo.2023.1300196.

References
1.
Smith T, Kahaly G, Ezra D, Fleming J, Dailey R, Tang R . Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med. 2017; 376(18):1748-1761. PMC: 5718164. DOI: 10.1056/NEJMoa1614949. View

2.
Samani A, Yakar S, LeRoith D, Brodt P . The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2006; 28(1):20-47. DOI: 10.1210/er.2006-0001. View

3.
Massague J, Czech M . The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor. J Biol Chem. 1982; 257(9):5038-45. View

4.
Patel A, Yang H, Douglas R . A New Era in the Treatment of Thyroid Eye Disease. Am J Ophthalmol. 2019; 208:281-288. DOI: 10.1016/j.ajo.2019.07.021. View

5.
Bahn R . Graves' ophthalmopathy. N Engl J Med. 2010; 362(8):726-38. PMC: 3902010. DOI: 10.1056/NEJMra0905750. View